Section/item	ltem No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	page 3/line 41	Abstract/paragraph 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	page 3-4/line 41-67	Abstract/paragraph 2-4
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	page 6/line 75-97	Introduction/paragraph 1
Objectives	3	State specific objectives, including any prespecified hypotheses	page 7/line 105-107	Introduction/paragraph 3
Methods				
Study design	4	Present key elements of study design early in the paper	page 7/line 111-115	Methods/paragraph 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	page 7-9/line 115-178	Methods/paragraph 1-4
Participants	6	 (a) <i>Cohort study</i>—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i>—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i>—Give the eligibility criteria, and the sources and methods of selection of participants 	page 7/line 111-115	Methods/paragraph 1
		(b) Cohort study —For matched studies, give matching criteria and number of exposed and unexposed Case-control study —For matched studies, give matching criteria and the number of controls per case	Not Applicable	Not Applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	page 8-10/line 129-193	Methods/paragraph 2-4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	page 8-9/line 129-185	Methods/paragraph 2-4
Bias	9	Describe any efforts to address potential sources of bias	page 7-9/line 117-178	Methods/paragraph 1-3
Study size	10	Explain how the study size was arrived at	Not Applicable	Not Applicable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	page 10/line 181-185	Methods/paragraph 5

STROBE Statement-checklist of items that should be included in reports of observational studies

12	(a) Describe all statistical methods, including those used to control for confounding	page 10-11/line 180-205	Methods/paragraph 5-6
	(b) Describe any methods used to examine subgroups and interactions	page 10-11/line 181-185	Methods/paragraph 5-6
	(c) Explain how missing data were addressed	Not Applicable	Not Applicable
	(d) Cohort study —If applicable, explain how loss to follow-up was addressed Case-control study —If applicable, explain how matching of cases and controls was addressed Cross-sectional study —If applicable, describe analytical methods taking account of sampling strategy	Not Applicable	Not Applicable
	(e) Describe any sensitivity analyses	Not Applicable	Not Applicable
13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	page 12/line 208	Results/paragraph 1
	(b) Give reasons for non-participation at each stage	Not Applicable	Not Applicable
	(c) Consider use of a flow diagram	Not Applicable	Not Applicable
14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	page 12-13/line 209-236	Results/paragraph 1,2
	(b) Indicate number of participants with missing data for each variable of interest	Not Applicable	Not Applicable
	(c) Cohort study —Summarise follow-up time (eg, average and total amount)	page 13/line 239	Results/paragraph 3
15*	Cohort study – Report numbers of outcome events or summary measures over time	page 13-14/line 239-254	Results/paragraph 3
	Case-control study – Report numbers in each exposure category, or summary measures of exposure	Not Applicable	Not Applicable
	Cross-sectional study – Report numbers of outcome events or summary measures	Not Applicable	Not Applicable
16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	page 13-14/line 239-254	Results/paragraph 3
	(b) Report category boundaries when continuous variables were categorized	page 13/line 241-245	Results/paragraph 3
	(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not Applicable	Not Applicable
17	Report other analyses done-eg analyses of subgroups and interactions, and sensitivity analyses	page 13-19/line 242-306	Results/paragraph 3-9
18	Summarise key results with reference to study objectives	page 16-17/line 312-337	Discussion/paragraph 1
19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction	page 21-22/line 403-429	Discussion/paragraph 6
	13* 14* 15* 16 17 18	(b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (a) Cohort study—If applicable, explain how loss to follow-up was addressed Cases-control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, explain how matching of cases and controls was addressed (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Cohort study—Summarise follow-up time (eg, average and total amount) 15* Cohort study—Report numbers of outcome events or summary measures ore time Case-control study—Report numbers of outcome events or summary measures (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categoriz	11 11 <td< td=""></td<>

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	page 17-20/line 332-397	Discussion/paragraph 2-4			
Generalisability	21	Discuss the generalisability (external validity) of the study results	page 20/line 398-402	Discussion/paragraph 5			
Other information							
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	page 23/line 438-441	Acknowledgements/paragr aph1			

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article Information: https://dx.doi.org/10.21037/tlcr-23-736

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.